Daiichi Sankyo Company, Limited (DSNKY) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Tokyo, Japan. The current CEO is Hiroyuki Okuzawa.
DSNKY has IPO date of 2008-12-12, 18,726 full-time employees, listed on the Other OTC, a market capitalization of $32.28B.
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, engaged in the research, development, manufacturing, and marketing of a diverse portfolio of prescription and over-the-counter medicines. The company's key therapeutic areas include oncology, cardiology, diabetes, neurology, and infectious diseases, with notable products such as trastuzumab deruxtecan for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo also operates in vaccines, animal health, cosmetics, medical devices, and active pharmaceutical ingredients. Founded in 1899, the company leverages strategic collaborations, including partnerships with diagnostic companies, to expand its competitive position in precision medicine and advanced therapies across major global markets.
